Mezavant (Mesalazine)

Mesalazine releases 5‑ASA in the colon, where it blocks cyclooxygenase and lipoxygenase enzymes, modulates local chemical mediators, and lowers cytokine production, thereby dampening the inflammatory response of the intestinal mucosa.

The dosage of Mezavant is individualized by the prescribing clinician based on disease severity, patient weight, and response. Patients should follow the exact regimen written on their prescription and not adjust the dose on their own.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians weigh potential benefits against risks, and the drug should only be used if clearly needed. Women should discuss any concerns with their healthcare provider.

To request Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant delivers mesalazine directly to the colon, similar to other 5‑ASA formulations such as sulfasalazine or balsalazide. Compared with sulfasalazine, Mezavant lacks a sulfapyridine moiety, which can reduce certain systemic side effects, while providing comparable anti‑inflammatory efficacy.

Mezavant should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability throughout its shelf life.

Mezavant is taken orally, usually with water. The tablets are swallowed whole and should be taken as directed by the prescriber, often with meals to minimise gastrointestinal discomfort.

Serious risks include severe allergic reactions such as anaphylaxis, myocarditis, pancreatitis, blood dyscrasias, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, chest pain, persistent abdominal pain, or unusual bruising.

Mezavant is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in patients with severe renal impairment or active severe infections unless specifically directed by a physician.